GlassScriptPhysician profile
Monica Lovins
NPI 1861732331
$17,821.61
in general payments reported to CMS, 2019-2025
39 companies · $7,098 in 2025
The $7,098 reported for 2025 was more than what 99% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,265 · 2022: $2,709 · 2023: $2,780 · 2024: $2,969 · 2025: $7,098.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,987 · Consulting Fee: $2,640 · Travel and Lodging: $1,041 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,986.74 |
| Consulting Fee | $2,640.00 |
| Travel and Lodging | $1,041.02 |
| Education | $179.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $5,566.50 | 2021-2025 | Livdelzi, Epclusa, Vemlidy |
| Abbvie INC. | $2,522.99 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,121.10 | 2021-2025 | Xifaxan, Trulance |
| Celgene Corporation | $1,080.89 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $1,053.88 | 2021-2025 | Stelara, Tremfya, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $643.20 | 2021-2025 | Entyvio, Eohilia |
| Qol Medical, LLC | $600.50 | 2021-2025 | Sucraid, Sucraid |
| Pfizer INC. | $555.44 | 2021-2025 | |
| Nestle Healthcare Nutrition INC. | $525.19 | 2021-2023 | |
| Madrigal Pharmaceuticals | $414.59 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $404.54 | 2022-2025 | Ibsrela |
| Amgen INC. | $321.66 | 2021-2023 | Avsola, Amjevita |
| Genzyme Corporation | $309.76 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $309.45 | 2021-2025 | Ocaliva |
| Pharmacosmos Therapeutics INC. | $197.97 | 2022-2023 | Monoferric |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $169.43 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $150.99 | 2022-2023 | Zeposia |
| Merck Sharp & Dohme LLC | $145.55 | 2022-2024 | Dificid, Zinplava |
| Novo Nordisk INC | $140.76 | 2025 | Wegovy |
| Horizon Therapeutics Plc | $138.61 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $138.22 | 2022-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $135.71 | 2021-2023 | Linzess |
| Aimmune Therapeutics, INC. | $129.42 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $120.00 | 2025 | Uptravi, Opsumit |
| Endo Pharmaceuticals INC. | $119.67 | 2021 | |
| Medtronic, INC. | $107.81 | 2025 | Pillcam |
| Lilly USA, LLC | $107.21 | 2023-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $104.14 | 2024-2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $85.42 | 2025 | Iqirvo |
| Janssen Scientific Affairs, LLC | $75.50 | 2023 | Stelara, Tremfya |
| Organon LLC | $71.15 | 2021-2022 | |
| Braintree Laboratories, INC. | $68.70 | 2021-2023 | Sutab |
| Redhill Biopharma INC. | $52.03 | 2021 | |
| Intra-Sana Laboratories | $36.01 | 2022-2023 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Fresenius Kabi USA, LLC | $30.85 | 2023 | Idacio |
| Celltrion USA INC. | $19.99 | 2024 | Zymfentra |
| Ferring Pharmaceuticals INC. | $19.73 | 2023 | Rebyota |
| Alnylam Pharmaceuticals INC. | $17.81 | 2022 | |
| Janssen Pharmaceuticals, INC | $9.24 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monica Lovins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.